From d4329bc17cc40c71b81d9d75a71c8d03fba9ad27 Mon Sep 17 00:00:00 2001 From: ahmedhaly7777 Date: Thu, 14 Nov 2024 13:12:02 -0500 Subject: [PATCH] Update A4a.cshtml Tailwind font updates --- src/UDS.Net.Forms/Pages/UDS4/A4a.cshtml | 16 ++++++++-------- 1 file changed, 8 insertions(+), 8 deletions(-) diff --git a/src/UDS.Net.Forms/Pages/UDS4/A4a.cshtml b/src/UDS.Net.Forms/Pages/UDS4/A4a.cshtml index bf12dceb..af8b1b89 100644 --- a/src/UDS.Net.Forms/Pages/UDS4/A4a.cshtml +++ b/src/UDS.Net.Forms/Pages/UDS4/A4a.cshtml @@ -8,7 +8,7 @@

- INSTRUCTIONS: This form should be used to record treatments expected to significantly impact Alzheimer disease and related dementias (ADRD) biomarkers, whether a disease-modifying treatment that is FDA-approved for ADRD and received as part of clinical care or an investigational treatment received as part of a clinical trial. For treatments received as part of clinical care, only those that are FDA-approved for disease-modification of ADRD should be included on this form. If the participant is receiving one of these treatments as part of their clinical care at the time of clinical assessment (e.g., they are receiving lecanemab infusions), the treatment should be included on both this form and the A4 Medication form. Participation in any ADRD drug trial over an individual's lifetime should be included. If available, the ClinicalTrials.gov identifier should be entered into the "specific treatment and/or trial" cell. Information on the type of treatment can be found via ClinicalTrials.gov and is summarized in "Alzheimer's disease drug development pipeline." 1 This form should be completed by the clinician based on participant interview and/or co-participant report. For additional clarification and examples, see for Form A4a. Check only one box per question, unless otherwise stated. + INSTRUCTIONS: This form should be used to record treatments expected to significantly impact Alzheimer disease and related dementias (ADRD) biomarkers, whether a disease-modifying treatment that is FDA-approved for ADRD and received as part of clinical care or an investigational treatment received as part of a clinical trial. For treatments received as part of clinical care, only those that are FDA-approved for disease-modification of ADRD should be included on this form. If the participant is receiving one of these treatments as part of their clinical care at the time of clinical assessment (e.g., they are receiving lecanemab infusions), the treatment should be included on both this form and the A4 Medication form. Participation in any ADRD drug trial over an individual's lifetime should be included. If available, the ClinicalTrials.gov identifier should be entered into the "specific treatment and/or trial" cell. Information on the type of treatment can be found via ClinicalTrials.gov and is summarized in "Alzheimer's disease drug development pipeline." 1 This form should be completed by the clinician based on participant interview and/or co-participant report. For additional clarification and examples, see for Form A4a. Check only one box per question, unless otherwise stated.

@@ -28,21 +28,21 @@

(If participant is exposed to more than two treatments and/or trials, use extended table below) -

+

Primary Drug Target

-

(check all that apply)

+

(check all that apply)

Specific treatment and/or trial - Start date (month/year) + Start date (month/year) - End date (month/year) + End date (month/year) How was the treatment provided? @@ -130,16 +130,16 @@

Primary Drug Target

-

(check all that apply)

+

(check all that apply)

Specific treatment and/or trial - Start date (month/year) + Start date (month/year) - End date (month/year) + End date (month/year) How was the treatment provided?